• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶瘤腺病毒与肝细胞相互作用的体内追踪

In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells.

作者信息

Naumenko Victor A, Vishnevskiy Daniil A, Stepanenko Aleksei A, Sosnovtseva Anastasiia O, Chernysheva Anastasiia A, Abakumova Tatiana O, Valikhov Marat P, Lipatova Anastasiia V, Abakumov Maxim A, Chekhonin Vladimir P

机构信息

V. Serbsky National Medical Research Center for Psychiatry and Narcology, 119034 Moscow, Russia.

Department of Medical Nanobiotechnology, N.I Pirogov Russian National Research Medical University, 117997 Moscow, Russia.

出版信息

Biomedicines. 2022 Jul 13;10(7):1697. doi: 10.3390/biomedicines10071697.

DOI:10.3390/biomedicines10071697
PMID:35885002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9313019/
Abstract

Hepatotoxicity remains an as yet unsolved problem for adenovirus (Ad) cancer therapy. The toxic effects originate both from rapid Kupffer cell (KCs) death (early phase) and hepatocyte transduction (late phase). Several host factors and capsid components are known to contribute to hepatotoxicity, however, the complex interplay between Ad and liver cells is not fully understood. Here, by using intravital microscopy, we aimed to follow the infection and immune response in mouse liver from the first minutes up to 72 h post intravenous injection of three Ads carrying delta-24 modification (Ad5-RGD, Ad5/3, and Ad5/35). At 15-30 min following the infusion of Ad5-RGD and Ad5/3 (but not Ad5/35), the virus-bound macrophages demonstrated signs of zeiosis: the formation of long-extended protrusions and dynamic membrane blebbing with the virus release into the blood in the membrane-associated vesicles. Although real-time imaging revealed interactions between the neutrophils and virus-bound KCs within minutes after treatment, and long-term contacts of CD8+ T cells with transduced hepatocytes at 24-72 h, depletion of neutrophils and CD8+ T cells affected neither rate nor dynamics of liver infection. Ad5-RGD failed to complete replicative cycle in hepatocytes, and transduced cells remained impermeable for propidium iodide, with a small fraction undergoing spontaneous apoptosis. In Ad5-RGD-immune mice, the virus neither killed KCs nor transduced hepatocytes, while in the setting of hepatic regeneration, Ad5-RGD enhanced liver transduction. The clinical and biochemical signs of hepatotoxicity correlated well with KC death, but not hepatocyte transduction. Real-time in vivo tracking for dynamic interactions between virus and host cells provides a better understanding of mechanisms underlying Ad-related hepatotoxicity.

摘要

肝毒性仍然是腺病毒(Ad)癌症治疗中一个尚未解决的问题。毒性作用既源于库普弗细胞(KCs)的快速死亡(早期阶段),也源于肝细胞转导(晚期阶段)。已知几种宿主因素和衣壳成分会导致肝毒性,然而,Ad与肝细胞之间复杂的相互作用尚未完全了解。在这里,我们通过活体显微镜检查,旨在追踪静脉注射三种携带delta-24修饰的Ad(Ad5-RGD、Ad5/3和Ad5/35)后,小鼠肝脏从最初几分钟到72小时的感染和免疫反应。在输注Ad5-RGD和Ad5/3(但不是Ad5/35)后的15 - 30分钟,与病毒结合的巨噬细胞出现了细胞溶解的迹象:形成长而延伸的突起以及动态的膜泡形成,病毒通过膜相关囊泡释放到血液中。尽管实时成像显示治疗后几分钟内中性粒细胞与病毒结合的KCs之间存在相互作用,以及24 - 72小时时CD8 + T细胞与转导的肝细胞之间存在长期接触,但中性粒细胞和CD8 + T细胞的耗竭既不影响肝脏感染的速率也不影响其动态过程。Ad5-RGD未能在肝细胞中完成复制周期,转导的细胞对碘化丙啶仍不可渗透,只有一小部分细胞发生自发凋亡。在Ad5-RGD免疫的小鼠中,病毒既不杀死KCs也不转导肝细胞,而在肝再生的情况下,Ad5-RGD增强了肝脏转导。肝毒性的临床和生化体征与KCs死亡密切相关,但与肝细胞转导无关。对病毒与宿主细胞之间动态相互作用的实时体内追踪有助于更好地理解Ad相关肝毒性的潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/9313019/0c7dea8b68b8/biomedicines-10-01697-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/9313019/4fe50d8df65f/biomedicines-10-01697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/9313019/3ea1a31b9aa4/biomedicines-10-01697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/9313019/0c7dea8b68b8/biomedicines-10-01697-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/9313019/4fe50d8df65f/biomedicines-10-01697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/9313019/3ea1a31b9aa4/biomedicines-10-01697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/9313019/0c7dea8b68b8/biomedicines-10-01697-g004.jpg

相似文献

1
In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells.溶瘤腺病毒与肝细胞相互作用的体内追踪
Biomedicines. 2022 Jul 13;10(7):1697. doi: 10.3390/biomedicines10071697.
2
Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.腺相关病毒2在体内进行肝脏转导时需要肝细胞硫酸乙酰肝素,但腺病毒5则不需要。
J Virol. 2015 Oct 21;90(1):412-20. doi: 10.1128/JVI.01939-15. Print 2016 Jan 1.
3
Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.多种冗余且协同的机制控制着血液中腺病毒在肝脏的潴留。
Mol Ther. 2009 Apr;17(4):675-84. doi: 10.1038/mt.2008.307. Epub 2009 Feb 17.
4
Circulating antibodies and macrophages as modulators of adenovirus pharmacology.循环抗体和巨噬细胞作为腺病毒药理学的调节剂。
J Virol. 2013 Apr;87(7):3678-86. doi: 10.1128/JVI.01392-12. Epub 2013 Jan 16.
5
Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver.全身递送的腺病毒载体与小鼠肝脏库普弗细胞的相互作用。
Hum Gene Ther. 2008 May;19(5):547-54. doi: 10.1089/hum.2008.004.
6
Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.溶瘤腺病毒 5 载体在癌症治疗中的趋向性和转导作用:重点关注纤维嵌合体和嵌合性、六邻体和 pIX。
Virus Res. 2018 Sep 15;257:40-51. doi: 10.1016/j.virusres.2018.08.012. Epub 2018 Aug 17.
7
Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.将腺病毒载体靶向肿瘤细胞并不能实现乳腺癌转移灶的有效转导。
Cancer Res. 2002 Feb 15;62(4):1063-8.
8
Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.操控腺病毒六邻体高变环可在体外和体内决定免疫中和作用以及凝血因子X依赖性细胞相互作用。
PLoS Pathog. 2015 Feb 6;11(2):e1004673. doi: 10.1371/journal.ppat.1004673. eCollection 2015 Feb.
9
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.整合素靶向溶瘤腺病毒 Ad5-D24-RGD 和 Ad5-RGD-D24-GMCSF 治疗晚期化疗耐药实体瘤患者。
Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8.
10
Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.联合纤维修饰靶向 α(v)β(6) 和去靶向柯萨奇病毒-腺病毒受体可改善体内病毒毒性谱,但与腺病毒 5 型相比,未能提高抗肿瘤疗效。
Hum Gene Ther. 2012 Sep;23(9):960-79. doi: 10.1089/hum.2011.218. Epub 2012 Aug 27.

引用本文的文献

1
Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms.溶瘤腺病毒与免疫检查点抑制剂的协同作用:转变癌症免疫治疗模式
Front Immunol. 2025 Jul 8;16:1610858. doi: 10.3389/fimmu.2025.1610858. eCollection 2025.
2
Adenoviruses Encapsulated in PEGylated DOTAP-Folate Liposomes Are Protected from the Pre-Existing Humoral Immune Response.包裹于聚乙二醇化的DOTAP-叶酸脂质体中的腺病毒可免受预先存在的体液免疫反应的影响。
Pharmaceutics. 2025 Jun 11;17(6):769. doi: 10.3390/pharmaceutics17060769.
3
Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation.

本文引用的文献

1
Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?非癌细胞的感染:溶瘤病毒疗法的障碍还是支持?
Mol Ther Oncolytics. 2022 Feb 12;24:663-682. doi: 10.1016/j.omto.2022.02.004. eCollection 2022 Mar 17.
2
Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.在原发性胶质瘤培养物中,纤维嵌合型溶瘤腺病毒Ad5/35和Ad5/3比Ad5-δ-24-RGD具有更高的感染性。
Mol Ther Oncolytics. 2021 Dec 21;24:230-248. doi: 10.1016/j.omto.2021.12.013. eCollection 2022 Mar 17.
3
Adenovirus vector-attributed hepatotoxicity blocks clinical application in gene therapy.
溶瘤病毒作为癌症治疗手段:从机制洞察到临床转化
Mol Ther. 2025 May 7;33(5):2217-2228. doi: 10.1016/j.ymthe.2025.03.035. Epub 2025 Mar 25.
4
Improving systemic delivery of oncolytic virus by cellular carriers.通过细胞载体改善溶瘤病毒的全身递送。
Cancer Biol Med. 2025 Jan 17;21(12):1104-19. doi: 10.20892/j.issn.2095-3941.2024.0390.
5
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.单次静脉注射溶瘤腺病毒 TILT-123 可导致晚期实体瘤患者全身肿瘤转导和免疫应答。
J Exp Clin Cancer Res. 2024 Nov 6;43(1):297. doi: 10.1186/s13046-024-03219-0.
6
The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.免疫系统——腺病毒疗法的双刃剑。
Viruses. 2024 Jun 17;16(6):973. doi: 10.3390/v16060973.
7
Emerging delivery strategy for oncolytic virotherapy.溶瘤病毒疗法的新兴递送策略。
Mol Ther Oncol. 2024 Apr 29;32(2):200809. doi: 10.1016/j.omton.2024.200809. eCollection 2024 Jun 20.
8
Erythrocyte-Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects.红细胞利用溶瘤病毒治疗(ELeOVt):红细胞表面的溶瘤病毒组装以对抗肺转移并减轻副作用。
Adv Sci (Weinh). 2024 Feb;11(5):e2303907. doi: 10.1002/advs.202303907. Epub 2023 Nov 23.
9
Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time.体积成像技术用于在时空上研究癌细胞-肿瘤微环境相互作用。
Front Immunol. 2023 May 16;14:1176594. doi: 10.3389/fimmu.2023.1176594. eCollection 2023.
腺病毒载体所致的肝毒性阻碍了其在基因治疗中的临床应用。
Cytotherapy. 2021 Dec;23(12):1045-1052. doi: 10.1016/j.jcyt.2021.07.013. Epub 2021 Sep 20.
4
A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation.在 CsCl 梯度超速离心过程中对溶瘤腺病毒 Ad5-delta-24-RGD 聚集的新认识。
Sci Rep. 2021 Aug 9;11(1):16088. doi: 10.1038/s41598-021-94573-y.
5
Comprehensive analysis of liver macrophage composition by flow cytometry and immunofluorescence in murine NASH.通过流式细胞术和免疫荧光技术对 NASH 小鼠肝脏巨噬细胞组成进行全面分析。
STAR Protoc. 2021 Apr 29;2(2):100511. doi: 10.1016/j.xpro.2021.100511. eCollection 2021 Jun 18.
6
Systemic cancer therapy with engineered adenovirus that evades innate immunity.利用可逃避先天免疫的工程腺病毒进行全身性癌症治疗。
Sci Transl Med. 2020 Nov 25;12(571). doi: 10.1126/scitranslmed.abc6659.
7
Live Imaging of Innate and Adaptive Immune Responses in the Liver.肝脏固有和适应性免疫反应的活体成像。
Front Immunol. 2020 Sep 17;11:564768. doi: 10.3389/fimmu.2020.564768. eCollection 2020.
8
Interaction of adenovirus with antibodies, complement, and coagulation factors.腺病毒与抗体、补体和凝血因子的相互作用。
FEBS Lett. 2019 Dec;593(24):3449-3460. doi: 10.1002/1873-3468.13649. Epub 2019 Nov 15.
9
Dynamics and genomic landscape of CD8 T cells undergoing hepatic priming.CD8 T 细胞在肝内启动过程中的动力学和基因组景观。
Nature. 2019 Oct;574(7777):200-205. doi: 10.1038/s41586-019-1620-6. Epub 2019 Oct 2.
10
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).一项评估腺病毒 Enadenotucirev(一种溶瘤病毒)治疗上皮性实体瘤患者的 I 期剂量递增研究(EVOLVE)。
J Immunother Cancer. 2019 Jan 28;7(1):20. doi: 10.1186/s40425-019-0510-7.